B+
Bull case
25%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
KROS
Keros TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The first-half 2027 DMD data window offers meaningful clinical upside, while the Takeda milestone validates contractual economics. Keros reported $257.6 million of cash at June 30, 2026 and projected funding into the first half of 2028.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.3.
What can break
Clinical spending and continued losses could erode the reported cash runway; future financing could dilute shareholders.
Momentum
71
Value
61
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.50 · Bull $17.00 · Bear $7.00Analysis 2026-10-23; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-23 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $19.83
Why
Momentum71 · Δ7d +7.8
Value61 · Δ7d +0.1
Sentiment67 · Δ7d -2.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -2.3.
Contradictions & invalidation
- • Clinical spending and continued losses could erode the reported cash runway; future financing could dilute shareholders.
- • Initial DMD patient data may be delayed, inconclusive or unfavorable despite Phase 1 activity in healthy volunteers.
- • Rinvatercept's benefit in DMD patients remains unproven, and trial timing or results could disappoint.
Catalyst clock
2026-12-31
Takeda elritercept milestone and proposed distribution
Lead driver: Sentiment · See AI snapshot
Momentum
71
8% active weight
Current posture
7d trendImproving
Δ7d
+7.8
Δ21d
+3.4
Value
61
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.1
Sentiment
67
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.3
Δ21d
-6.5
Why this grade
Composite grade A. Momentum 70.6 / Value 61.3 / Sentiment 67.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-23. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$226.53M
Beta
0.87
Shares Out
19.83M
P/E (TTM)
11.6
P/S (TTM)
2.21
P/FCF (TTM)
6.27
Rev YoY
-100.0%
EPS YoY
+91.8%
Gross Margin
+89.3%
Op Margin
-332.3%
Net Debt
-$270.53M
Current Ratio
21.96
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data